Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Cash from Operations (2021 - 2025)

Krystal Biotech's Cash from Operations history spans 5 years, with the latest figure at 77508000.0 for Q4 2025.

  • For Q4 2025, Cash from Operations rose 46.68% year-over-year to 77508000.0; the TTM value through Dec 2025 reached 200865000.0, up 62.75%, while the annual FY2025 figure was 200865000.0, 62.75% up from the prior year.
  • Cash from Operations for Q4 2025 was 77508000.0 at Krystal Biotech, up from 39659000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 77508000.0 in Q4 2025 and bottomed at 43059000.0 in Q2 2022.
  • The 5-year median for Cash from Operations is 8454500.0 (2021), against an average of 4348700.0.
  • The largest annual shift saw Cash from Operations tumbled 325.11% in 2022 before it soared 1365.09% in 2025.
  • A 5-year view of Cash from Operations shows it stood at 20900000.0 in 2021, then dropped by 6.84% to 22329000.0 in 2022, then soared by 67.61% to 7232000.0 in 2023, then soared by 830.68% to 52843000.0 in 2024, then skyrocketed by 46.68% to 77508000.0 in 2025.
  • Per Business Quant, the three most recent readings for KRYS's Cash from Operations are 77508000.0 (Q4 2025), 39659000.0 (Q3 2025), and 52729000.0 (Q2 2025).